Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.12M | 6.83M | 8.10M | 9.90M | 14.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.09M | 9.39M | 10.54M | 11.31M | 16.17M |
| Operating Income | -6.09M | -9.39M | -10.54M | -11.31M | -16.17M |
| Income Before Tax | -5.88M | -9.22M | -10.41M | -11.25M | -16.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.88 | -9.22 | -10.41 | -11.25 | -16.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.88M | -9.22M | -10.41M | -11.25M | -16.14M |
| EBIT | -6.09M | -9.39M | -10.54M | -11.31M | -16.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.91 | -0.29 | -0.34 | -0.37 | -0.54 |
| Normalized Basic EPS | -0.10 | -0.18 | -0.21 | -0.23 | -0.34 |
| EPS Diluted | -0.91 | -0.29 | -0.34 | -0.37 | -0.54 |
| Normalized Diluted EPS | -0.10 | -0.18 | -0.21 | -0.23 | -0.34 |
| Average Basic Shares Outstanding | 161.11M | 130.28M | 125.66M | 121.83M | 119.04M |
| Average Diluted Shares Outstanding | 161.11M | 130.28M | 125.66M | 121.83M | 119.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |